drugset
drugset / Trial / NCT00707655

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

NCT00707655 ↗

Phase 1/2 Terminated 8 enrolled Genmab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety of zalutumumab in combination with radiotherapy as the treatment of patients with head and neck cancer who are not eligible for platinum based chemotherapy.

Timeline

Start
2008-09
Primary completion
2010-10
Completion
2010-10

Outcome

Outcome not reported

Stopped: “The decision is based on company re-evaluation of indications to be pursued within SCCHN”

Drugs

EvaluationDrugModalityDoseRoute
Subject Zalutumumab Monoclonal antibody 4 mg/kg Other
Subject Zalutumumab Monoclonal antibody 8 mg/kg Other

Indications

head and neck cancer squamous cell carcinoma